CIK: 0001958125
Total reported value
$478.7M
Reporting period: 2026-03-31 · Number of holdings: 41
Catalio Capital Management, LP disclosed 41 holdings in its latest 13F filing for the period ending 2026-03-31, with total reported value of $478.7M and a quarterly turnover rate of 86.4%.
Browse other institutions with $100M to $1B AUMBrowse other institutions starting with "C"
Catalio Capital Management, LP's disclosed holdings carry a Herfindahl concentration index of 0.043 — mathematically equivalent to about 23 equally-sized positions, well below its 41 actual disclosed holdings. That gap points to a strategy built around a small core of high-conviction bets rather than broad diversification.
Position sizes are fairly uniform across the portfolio (a coefficient of variation of 0.88), suggesting a disciplined, rules-based approach to how much capital goes into each idea.
No strong tilt toward either adding to existing winners or initiating outsized new positions was observed in the latest reported quarter.
Sector classification currently covers about 33% of this portfolio's disclosed value; the remainder includes holdings (e.g. unmapped tickers, options, or other security types) not yet covered by our sector mapping.
Add DNTH
-14.3% $20.1M
Add 430
+198.7% $16.0M
Add RARE
+423.4% $14.1M
Trim BSX
-17.0% -$15.6M
Add ASND
+8.3% $4.1M
Trim GUTS
0.0% -$9.6M
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | DNTH | Dianthus Therapeutics INC | Stock-Other | 9.82% | +5.06% | -14.27% | |
| 2 | BBIO | Bridgebio Pharma INC | Stock-Healthcare | 6.70% | +6.70% | NEW | |
| 3 | ASND | Ascendis Pharma A/S | Stock-Other | 6.17% | +1.67% | +8.26% | |
| 4 | BMY | Bristol-myers Squibb Co | Stock-Healthcare | 5.33% | -0.85% | -35.06% | |
| 5 | SNDX | Syndax Pharmaceuticals INC | Stock-Other | 5.09% | +0.65% | -12.80% | |
| 6 | GILD | Gilead Sciences INC | Stock-Healthcare | 4.77% | -1.51% | -43.35% | |
| 7 | 430 | Terns Pharmaceuticals INC | Stock-Other | 4.50% | +3.52% | +198.65% | |
| 8 | DFTX | Definium Therapeutics INC | Stock-Other | 4.10% | +4.10% | NEW | |
| 9 | SLNOEUR | Soleno Therapeutics INC | Stock-Other | 4.04% | +1.09% | +60.35% | |
| 10 | BSX | Boston Scientific CORP | Stock-Healthcare | 3.92% | -2.15% | -16.95% | |
| 11 | RARE | Ultragenyx Pharmaceutical In | Stock-Other | 3.72% | +3.06% | +423.41% | |
| 12 | INCY | Incyte CORP | Stock-Healthcare | 3.58% | +3.58% | NEW | |
| 13 | CYTK | Cytokinetics INC | Stock-Healthcare | 2.97% | +0.07% | -16.60% | |
| 14 | NTRA | Natera INC | Stock-Healthcare | 2.96% | — | +13.86% | |
| 15 | CRVS | Corvus Pharmaceuticals INC | Stock-Other | 2.73% | +2.73% | NEW | |
| 16 | GPCR | Structure Therapeutics INC | Stock-Other | 2.57% | -0.54% | +0.98% | |
| 17 | MLYS | Mineralys Therapeutics INC | Stock-Other | 2.48% | — | +32.30% | |
| 18 | EW | Edwards Lifesciences CORP | Stock-Healthcare | 2.42% | -0.40% | -22.69% | |
| 19 | MANE | Veradermics INC | Stock-Other | 2.29% | +2.29% | NEW | |
| 20 | ADPT | Adaptive Biotechnologies | Stock-Other | 2.10% | -0.26% | -11.98% | |
| 21 | HTFL | Heartflow INC | Stock-Other | 2.05% | +1.46% | +254.47% | |
| 22 | 4XC1 | Kalvista Pharmaceuticals INC | Stock-Other | 1.79% | +1.79% | NEW | |
| 23 | QURE | uniQure N.V. | Stock-Other | 1.68% | +0.46% | +70.32% | |
| 24 | IRON | Disc Medicine INC | Stock-Other | 1.64% | +0.09% | +11.37% | |
| 25 | SEPN | Septerna INC | Stock-Other | 1.48% | +0.03% | — | |
| 26 | ABVX | Abivax Sa-adr | Stock-Other | 1.10% | -1.25% | -52.10% | |
| 27 | DYN | Dyne Therapeutics INC | Stock-Other | 1.07% | -0.73% | -45.56% | |
| 28 | ELDN | Eledon Pharmaceuticals INC | Stock-Other | 1.06% | +0.72% | +30.16% | |
| 29 | KPTI | Karyopharm Therapeutics INC | Stock-Other | 1.04% | +0.85% | +527.84% | |
| 30 | SUPN | Supernus Pharmaceuticals INC | Stock-Healthcare | 0.67% | -1.59% | -75.91% | |
| 31 | TARA | Protara Therapeutic INC | Stock-Other | 0.63% | -0.73% | -59.89% | |
| 32 | PHAT | Phathom Pharmaceuticals INC | Stock-Other | 0.58% | -1.48% | -64.55% | |
| 33 | NAMS | NewAmsterdam Pharma Company N.V. | Stock-Other | 0.56% | +0.56% | NEW | |
| 34 | TYRA | Tyra Biosciences INC | Stock-Other | 0.54% | +0.54% | NEW | |
| 35 | IMCR | Immunocore Holdings Plc-adr | Stock-Other | 0.53% | +0.53% | NEW | |
| 36 | GUTS | Fractyl Health INC | Stock-Other | 0.53% | -1.61% | — | |
| 37 | HYPR | Hyperfine INC | Stock-Other | 0.30% | — | — | |
| 38 | MGX | Metagenomi Therapeutics INC | Stock-Other | 0.15% | — | — | |
| 39 | ATAI | Ataibeckley INC | Stock-Other | 0.15% | +0.15% | NEW | |
| 40 | FTH | Faeth Therapeutics INC | Stock-Other | 0.10% | +0.07% | — | |
| 41 | OM | Outset Medical INC | Stock-Other | 0.09% | — | — |
Performance for Q3 2026
+19.3%
Performance Last 4 Quarters
+64.2%
Based on 76% of reported portfolio value with available pricing
Catalio Capital Management, LP's most significant position changes for 2026-03-31: New buy: Bridgebio Pharma INC (BBIO); Sold out: Bridgebio Oncology Therapeut (BBOT); Sold out: Eli Lilly & Co (LLY); Sold out: Johnson & Johnson (JNJ); Sold out: Regeneron Pharmaceuticals (REGN).
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | DNTH | Dianthus Therapeutics INC | +5.1% | -14.27% | Trim |
| 2 | 430 | Terns Pharmaceuticals INC | +3.5% | +198.65% | Add |
| 3 | RARE | Ultragenyx Pharmaceutical In | +3.1% | +423.41% | Add |
| 4 | ASND | Ascendis Pharma A/S | +1.7% | +8.26% | Add |
| 5 | HTFL | Heartflow INC | +1.5% | +254.47% | Add |
| 6 | SLNOEUR | Soleno Therapeutics INC | +1.1% | +60.35% | Add |
| 7 | KPTI | Karyopharm Therapeutics INC | +0.9% | +527.84% | Add |
| 8 | ELDN | Eledon Pharmaceuticals INC | +0.7% | +30.16% | Add |
| 9 | SNDX | Syndax Pharmaceuticals INC | +0.7% | -12.80% | Trim |
| 10 | QURE | uniQure N.V. | +0.5% | +70.32% | Add |
| 11 | IRON | Disc Medicine INC | +0.1% | +11.37% | Add |
| 12 | CYTK | Cytokinetics INC | +0.1% | -16.60% | Trim |
| 13 | FTH | Faeth Therapeutics INC | +0.1% | — | Unchanged |
| 14 | SEPN | Septerna INC | 0% | — | Unchanged |
| 15 | ADPT | Adaptive Biotechnologies | -0.3% | -11.98% | Trim |
| 16 | EW | Edwards Lifesciences CORP | -0.4% | -22.69% | Trim |
| 17 | GPCR | Structure Therapeutics INC | -0.5% | +0.98% | Add |
| 18 | DYN | Dyne Therapeutics INC | -0.7% | -45.56% | Trim |
| 19 | TARA | Protara Therapeutic INC | -0.7% | -59.89% | Trim |
| 20 | BMY | Bristol-myers Squibb Co | -0.9% | -35.06% | Trim |
| 21 | ABVX | Abivax Sa-adr | -1.3% | -52.10% | Trim |
| 22 | PHAT | Phathom Pharmaceuticals INC | -1.5% | -64.55% | Trim |
| 23 | GILD | Gilead Sciences INC | -1.5% | -43.35% | Trim |
| 24 | SUPN | Supernus Pharmaceuticals INC | -1.6% | -75.91% | Trim |
| 25 | GUTS | Fractyl Health INC | -1.6% | — | Unchanged |
| 26 | BSX | Boston Scientific CORP | -2.2% | -16.95% | Trim |
| 27 | BBIO | Bridgebio Pharma INC | — | NEW | New buy |
| 28 | BBOT | Bridgebio Oncology Therapeut | — | EXIT | Sold out |
| 29 | LLY | Eli Lilly & Co | — | EXIT | Sold out |
| 30 | JNJ | Johnson & Johnson | — | EXIT | Sold out |
| 31 | REGN | Regeneron Pharmaceuticals | — | EXIT | Sold out |
| 32 | DFTX | Definium Therapeutics INC | — | NEW | New buy |
| 33 | INCY | Incyte CORP | — | NEW | New buy |
| 34 | ISRG | Intuitive Surgical INC | — | EXIT | Sold out |
| 35 | CRVS | Corvus Pharmaceuticals INC | — | NEW | New buy |
| 36 | MANE | Veradermics INC | — | NEW | New buy |
| 37 | ADMA | Adma Biologics INC | — | EXIT | Sold out |
| 38 | ACLXGBX | Arcellx INC | — | EXIT | Sold out |
| 39 | OCUL | Ocular Therapeutix INC | — | EXIT | Sold out |
| 40 | 4XC1 | Kalvista Pharmaceuticals INC | — | NEW | New buy |
| 41 | OLMA | Olema Pharmaceuticals INC | — | EXIT | Sold out |
| 42 | NAMS | NewAmsterdam Pharma Company N.V. | — | NEW | New buy |
| 43 | GRAL | Grail INC | — | EXIT | Sold out |
| 44 | TYRA | Tyra Biosciences INC | — | NEW | New buy |
| 45 | IMCR | Immunocore Holdings Plc-adr | — | NEW | New buy |
| 46 | FULC | Fulcrum Therapeutics INC | — | EXIT | Sold out |
| 47 | BLLN | Billiontoone INC Cl A | — | EXIT | Sold out |
| 48 | PVLA | Palvella Therapeutics INC | — | EXIT | Sold out |
| 49 | ATAI | AtaiBeckley Inc. | — | EXIT | Sold out |
| 50 | ATAI | Ataibeckley INC | — | NEW | New buy |
| Period | Filed | Type | EDGAR |
|---|---|---|---|
| 2026-03-31 | 2026-05-15 | 13F-HR | View on EDGAR |
| 2025-12-31 | 2026-02-17 | 13F-HR | View on EDGAR |
| 2025-09-30 | 2025-11-14 | 13F-HR | View on EDGAR |
| 2025-06-30 | 2025-08-14 | 13F-HR | View on EDGAR |
| 2025-03-31 | 2025-05-15 | 13F-HR | View on EDGAR |
| 2024-12-31 | 2025-02-14 | 13F-HR | View on EDGAR |
Institutions with a similar AUM
CIK 0001919438
Total reported value
$478.8M
155 stks
2026-06-30
AUM within 0.0% of this institution
CIK 0001853019
Total reported value
$478.8M
97 stks
2023-12-31
Stale — no recent filing
AUM within 0.0% of this institution
CIK 0001767730
Total reported value
$478.3M
167 stks
2026-03-31
AUM within 0.1% of this institution
Institutions with overlapping top holdings
CIK 0001766721
Total reported value
$476.3M
13 stks
2026-03-31
2 of the top 5 holdings overlap, including Bridgebio Pharma INC
CIK 0001892770
Total reported value
$168.0M
88 stks
2026-03-31
2 of the top 5 holdings overlap, including Syndax Pharmaceuticals INC
CIK 0000763848
Total reported value
$2.2B
152 stks
2020-09-30
Stale — no recent filing
1 of the top 5 holdings overlap, including Bristol-myers Squibb Co